{"id":2307,"date":"2017-09-15T10:14:33","date_gmt":"2017-09-15T04:44:33","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2307"},"modified":"2021-07-24T12:56:50","modified_gmt":"2021-07-24T07:26:50","slug":"business-cocktail-12","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12","title":{"rendered":"Business cocktail"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Bayer and Berkeley Lights embark on a project to automate drug discovery<\/strong><\/p>\n<p style=\"text-align: justify;\">Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights\u2019 platform- Beacon- aims to automate biological processes in the drug development process.<\/p>\n<p style=\"text-align: justify;\"><strong>Merger between Rocket and Inotek bags Nasdaq listing, aims to conduct gene therapy trials<\/strong><\/p>\n<p style=\"text-align: justify;\">Rocket Pharmaceuticals merged with Inotek through reverse merger process, and grabbed a NASDAQ listing in the process. The deal has now started the process of gene therapy research, and Inotek pharmaceuticals resources will help start some clinical trials on the same. The deal spells out the shareholding capacity of Rocket to 81%, leaving Inotek 19%. This stake provides information of the value Inotek has on the Nasdaq listing, all of what was left of its $27.6 million cash it had at the last count.<\/p>\n<p style=\"text-align: justify;\"><strong>Onexo\u2019s failure in Phase 3 hepatocellular carcinoma spells disaster for the company<\/strong><\/p>\n<p style=\"text-align: justify;\">Livatag, Onxeo\u2019s drug for hepatocellular carcinoma, has failed to show superiority against the active comparator in the clinical trials in its HCC trial. The results led to a 50% decline in the share price of Onexo as investors readjusted to the decreased expectations from the doxorubicin-loaded nanoparticle candidate.<\/p>\n<p style=\"text-align: justify;\"><strong>Funding round provides BridgeBio Pharma $135M for genetic disease work<\/strong><\/p>\n<p style=\"text-align: justify;\">The Californian biotech company, BridgeBio Pharma, earned $135 million to develop its genetic disease R&amp;D portfolio. This funding came through a spectrum of funders as well as investors, including Viking Global Investors, which is a new investor, along with old players of the market such as KKR. Apart from these two, Perceptive Advisors, AIG, Aisling Capital, Cormorant Capital and Janus Funds also joined the fray.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights\u2019 platform- Beacon- aims to automate biological processes in the drug [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1200,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[107,17571,2470,134,173,180,204,258,17574,17576,5996,17573,356,1387,17575,17572],"industry":[17225],"therapeutic_areas":[17238,17228],"class_list":["post-2307","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-bayer","tag-berkeley-lights","tag-bridgebio-pharma","tag-business-consultant","tag-collaborations","tag-competitive-landscape","tag-delveinsight","tag-gene-therapy","tag-gene-therapy-trials","tag-genetic-disease","tag-hepatocellular-carcinoma","tag-inotek","tag-licensing-opportunities","tag-nasdaq","tag-onexo","tag-rocket","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Bayer and Berkeley Lights embark on a project to automate drug discovery<\/title>\n<meta name=\"description\" content=\"harmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bayer and Berkeley Lights embark on a project to automate drug discovery\" \/>\n<meta property=\"og:description\" content=\"harmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-15T04:44:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bayer and Berkeley Lights embark on a project to automate drug discovery","description":"harmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12","og_locale":"en_US","og_type":"article","og_title":"Bayer and Berkeley Lights embark on a project to automate drug discovery","og_description":"harmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2017-09-15T04:44:33+00:00","article_modified_time":"2021-07-24T07:26:50+00:00","og_image":[{"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","width":1,"height":1,"type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12","name":"Bayer and Berkeley Lights embark on a project to automate drug discovery","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","datePublished":"2017-09-15T04:44:33+00:00","dateModified":"2021-07-24T07:26:50+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"harmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-12"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-12#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","caption":"Blue globes from drug capsule"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2016\/09\/15170357\/14130776__original.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bayer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Berkeley Lights<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BridgeBio Pharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Business Consultant<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">collaborations<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Competitive landscape<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene Therapy Trials<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Genetic Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Inotek<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">licensing opportunities<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Nasdaq<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Onexo<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rocket<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Bayer<\/span>","<span class=\"advgb-post-tax-term\">Berkeley Lights<\/span>","<span class=\"advgb-post-tax-term\">BridgeBio Pharma<\/span>","<span class=\"advgb-post-tax-term\">Business Consultant<\/span>","<span class=\"advgb-post-tax-term\">collaborations<\/span>","<span class=\"advgb-post-tax-term\">Competitive landscape<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapy Trials<\/span>","<span class=\"advgb-post-tax-term\">Genetic Disease<\/span>","<span class=\"advgb-post-tax-term\">Hepatocellular Carcinoma<\/span>","<span class=\"advgb-post-tax-term\">Inotek<\/span>","<span class=\"advgb-post-tax-term\">licensing opportunities<\/span>","<span class=\"advgb-post-tax-term\">Nasdaq<\/span>","<span class=\"advgb-post-tax-term\">Onexo<\/span>","<span class=\"advgb-post-tax-term\">Rocket<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 9 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 15, 2017","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Sep 15, 2017 10:14 am","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"Blue globes from drug capsule","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2307"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2307\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/1200"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2307"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2307"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}